drugset

drugset / Trial / NCT07585513

Beta-3 Enhanced Autonomic Therapy for POTS

NCT07585513 ↗

Phase 2 Not yet recruiting 36 enrolled Cedars-Sinai Medical Center

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study will test the hypothesis that mirabegron is more effective than a placebo in alleviating postural orthostatic tachycardia (POTS) symptoms.

Timeline

Start: 2026-05
Primary completion: 2028-05
Completion: 2028-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Mirabegron	Other / unclassified	25 mg	—

Indications